Sublingual immunotherapy with a standardized cat dander extract: Evaluation of efficacy in a double blind placebo controlled study

Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain
Allergy (Impact Factor: 6.03). 08/2007; 62(7):810-7. DOI: 10.1111/j.1398-9995.2007.01365.x
Source: PubMed


Little information is available on the clinical efficacy of sublingual immunotherapy (SLIT) using extracts derived from mammalian epithelia.
To assess clinical efficacy of cat SLIT based on natural exposure challenge test (NCT).
Fifty cat allergic patients with rhinoconjunctivitis with or without asthma were included in a randomized double blind placebo controlled clinical trial of cat SLIT during 1 year. Twenty-five patients received active treatment and 25 placebo. Sublingual immunotherapy efficacy was assessed by natural exposure challenge to a cat in a cat-room and by skin tests. Airborne Fel d 1 levels, symptom scores and peak expiratory flow (PEF) values were monitored.
Thirty-three (66%) out of 50 patients completed the treatment. Fel d 1 content of the maximum concentration was 0.51 microg per ml. During the build up phase, the accumulated dose was 1.7 mug of Fel d 1 and during the entire length of the study was 17.1. No adverse reports were reported. The active group showed a marked reduction (62%) in symptoms during the NCT (P < 0.001) with no changes in placebo group. Active group also showed a reduced PEF response to cat exposure (P < 0.05), and an improvement in skin test reactivity to a standardized cat extract (P < 0.05), without significant changes in placebo group. Mean Fel d 1 exposure during the NCT was 6.2 +/- 2.21 ng/m(3).
The results suggest that the cat SLIT used in this study was able to improve cat allergy based on natural exposure challenge.

Download full-text


Available from: Javier Cuesta-Herranz, Jan 28, 2015
  • Source
    • "Other variables such as dosing frequency, extract quality, and length of treatment also need to be considered. Numerous studies have observed and suggested a limited capacity of the sublingual mucosa and have shown clinical improvement with lower, but more frequent doses [11–13]. Patients were advised to take their sublingual immunotherapy drops three times daily. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Due to its excellent safety profile, ease of administration, and economic considerations, sublingual immunotherapy (SLIT) is becoming a preferred form of allergen specific immunotherapy. The efficacy of SLIT is still debated. The purpose of this act of practice trial is to evaluate quality of life outcomes in patients treated with SLIT. Fifty one patients with allergic rhinoconjunctivitis demonstrated by skin testing completed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) at initiation, at four months and at 10-12 months of SLIT. Significant improvement (P < 0.05) on six of seven domain categories of the RQLQ questionnaire was noted. Total RQLQ scores also showed significant improvement. This study supports SLIT as a modality effective in controlling allergic symptoms.
    Full-text · Article · Jan 2012 · Journal of Allergy
  • [Show abstract] [Hide abstract]
    ABSTRACT: An increasing number of clinical immunotherapy trials have been published in the United States and Europe. In the allergy community on both sides of the Atlantic, there is a growing interest in obtaining a better understanding of the allergen doses used in these studies. The question of effective allergen dose is particularly important in sublingual immunotherapy, but the effective dose range still is to be determined.
    No preview · Article · Mar 2008 · Allergy and Asthma Proceedings
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews the safety and efficacy of sublingual immunotherapy (SLIT) in the treatment of allergic rhinitis. The literature from 1986 through 2007 shows approximately a 6000-fold range in doses found to be effective with SLIT. However, recent studies in large patient populations have demonstrated a clear dose response with an effective dose range that appears to be equivalent to one to two times the monthly subcutaneous immunotherapy dose administered daily or weekly (ie, 15 to 30 microg of major allergen). Further study is needed to establish the optimal dose and dosing schedule for each formulation. Local reactions (eg, oral itchiness) are common, and serious adverse reactions, although rare, have been reported. Cost-effective analysis cannot be made until the effective dose is established. SLIT appears to be a promising treatment for allergic rhinitis, but it is currently considered investigational in the United States until a formulation approved by the US Food and Drug Administration is available.
    Preview · Article · May 2008 · Current Allergy and Asthma Reports
Show more